RxDoctor Payments Data

Thomas Marino, MD

Cardiovascular Disease · Schenectady, NYNPI 1912013475

Payments from drug & device makers

$1,125in general payments, 2019–2025

Across 57 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$165
  • Novartis$140
  • Boston Scientific$106
  • Merck$89
  • Johnson & Johnson$83
  • E.r. Squibb & Sons, L.L.C.$72
  • plus $469 from 15 others

What the payments were for

  • Food & beverage$1,09697%
  • Education$293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,125 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$61,547
Medicare patients
389
Services billed
861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$120,061
JardianceEmpagliflozin20$30,160
Repatha SureclickEvolocumab16$21,932
EntrestoSacubitril/Valsartan13$20,654
FarxigaDapagliflozin Propanediol11$16,100
Clonidine11$2,760
Atorvastatin Calcium121$1,833
Nifedipine ErNifedipine39$1,465
Ezetimibe44$1,324
Losartan Potassium75$1,001
Metoprolol Succinate58$885
Rosuvastatin Calcium62$868
Carvedilol53$551
Olmesartan Medoxomil12$520
Valsartan11$469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$120,06173 claims
Boehringer IngelheimJardiance$69$30,16020 claims
NovartisEntresto$140$20,65413 claims
AstraZenecaFarxiga$38$16,10011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →